The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules
Open accessAbstract
Cancer therapies using genes and other macromolecules might realize their full clinical potential if they could be delivered to tumor tissue in optimal quantities. Unfortunately, the compromised circulation within tumors poses a formidable resistance to adequate and uniform penetration of these agents. Previously, we have proposed elevated interstitial fluid pressure (IFP) as a major physiological barrier to delivery of macromolecules. Here we postulate that modulation of tumor microvascular pressure (MVP) and associated changes in IFP would enhance macromolecular delivery into a solid tumor. To test our hypothesis, we altered tumor MVP by either periodic injection or continuous infusion of angiotensin II (AII) and measured the resulting changes in IFP and uptake of macromolecules. We used the nicotinyl hydrazine derivative of human polyclonal IgG (HYNIC-IgG) as a nonspecific macromolecule and CC49 antibody as a specific macromolecule. We found that both chronic and periodic modulation of tumor MVP enhances transvascular fluid filtration, leading to a 40% increase in total uptake of the specific antibody within 4 hr of its administration. Conversely, neither continuous nor periodic infusion of AII induced any increase in uptake of nonspecific antibodies. Strategies to improve delivery of macromolecules and limitations of this approach are identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zlotecki, R. A., Baxter, L. T., Boucher, Y., & Jain, R. K. (1995) · Microvascular Research · doi:10.1006/mvre.1995.1069 · Cited by 91
Self-citation
Cited by
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
“In animal models, it has been shown that this can be done by periodically increasing the systemic blood pressure, such as by infusion of ANGIOTENSIN II , which leads to an increase in the hydrostatic pressure in capillaries and, therefore, a transiently increased gradient compared with the interstitiu”
ResultProvenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
“…envision the intravascular and interstitial compartments to be in contiguity or communication, suggesting that changes in IFP chronicle and directly reflect intratumoral vascular pressures largely as a consequence of ‘‘leaky’’ or damaged vessels (Boucher and Jain, 1992; Netti et al., 1999).”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
VEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
“As a matter of fact, these two pressures are so closely coupled that changing the vascular pressure leads to similar changes in the IFP within seconds, until they both become equal again (20).”
BackgroundSelf-citationColloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
Paciotti, G. F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R. E., & Tamarkin, L. (2004) · Drug Delivery · doi:10.1080/10717540490433895 · Cited by 1,185
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Self-citationMechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
“Interstitial hydrodynamic and oncotic pressures play a key role in the convection of nanoparticles through the vascular wall, which are directly affected by the haphazard traffic of fluids [41].”
BackgroundJain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612
“Tumor vessel leakiness is so extreme that a sudden, pharmacologically induced change in MVP results in an equivalent change in IFP, delayed by only about 10 s (6, 7).”
BackgroundSelf-citationPluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Self-citationDelivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Self-citationStylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationTumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium
Ramanujan, S., Pluen, A., McKee, T. D., Brown, E. B., Boucher, Y., & Jain, R. K. (2002) · Biophysical Journal · doi:10.1016/s0006-3495(02)73933-7 · Cited by 552
Self-citationMoradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Photoswitchable Nanoparticles for Triggered Tissue Penetration and Drug Delivery
Tong, R., Hemmati, H. D., Langer, R., & Kohane, D. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211888a · Cited by 477
(1999) · PubMed · Cited by 348
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 334
Jain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
Self-citation(2000) · PubMed · Cited by 295
Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor
JAIN, R. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70063-8 · Cited by 256
Self-citationEikenes, L., Bruland, Ø. S., Brekken, C., & Davies, C. D. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1472 · Cited by 251
Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase
DuFort, C. C., DelGiorno, K. E., Carlson, M. A., Osgood, R. J., Zhao, C., Huang, Z., Thompson, C. B., Connor, R. J., Thanos, C. D., Scott Brockenbrough, J., et al. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.03.040 · Cited by 171
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
DuFort, C. C., DelGiorno, K. E., & Hingorani, S. R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.040 · Cited by 144
Lammers, T., Peschke, P., Kühnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., & Storm, G. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.032 · Cited by 124
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53
Metadata
- Authors
- Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstead, D., Graham, W., Hunter, G. J., Wolf, G. L., Fischman, A., Boucher, Y., & Jain, R. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-03-16
- Volume
- 96
- Issue
- 6
- Pages
- 3137-3142
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2002268410
- Cited by
- 202
- References
- 1
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.